Phase 3 Readout

AGIO: Phase 3 Topline: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanc

Name: Phase 3 Topline: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanc
Start: 2027-12-01
End: 2027-12-01

December 1, 2027 · ivosidenib. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2027
Company: AGIOS PHARMACEUTICALS, INC. (AGIO)
Drug: ivosidenib

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanc

December 1, 2027

AGIO overview →

Company: AGIOS PHARMACEUTICALS, INC. (AGIO)
Drug: ivosidenib
Indication: Cholangiocarcinoma